Clinical Research Directory

Inclusion Criteria: * Age \>18 years old. * \>12 months and \< 24 months post transplantation. * Liver transplant for non-immune liver disease. * For participants with HCV (history of HCV or donor with history of HCV): must be HCV PCR negative and have documented history of Sustained Viral Response to antiviral therapy (\>=12 weeks) or documented, persistent spontaneous clearance of HCV. * For participants with HBV: must be controlled with HBV antiviral treatment and anticipate receiving continuing HBV antiviral treatment for the duration of study participation. * Receiving maintenance IS with a CNI (tacrolimus, cyclosporin). * No history of BPAR in the prior 6 months. * Stable immunosuppression for the prior 3 months. * No history of chronic rejection. * No known clinical history of cirrhosis post-transplant. * Liver chemistry tests: total bilirubin, ALT, AST, GGT, and alkaline phosphatase all \<= ULN for the prior 3 months. * Stable renal function, with eGFR \>= 30 ml/min/1.73m2 by CKD-EPI (2021). * For participants known to have a history of TB or latent TB infection, documented history of completing appropriate treatment. * Participants of childbearing potential must have a negative pregnancy test upon study entry. * All participants with reproductive potential, must agree to use FDA approved methods of birth control for the duration of the study (http://www.fda.gov/birthcontrol). * Vaccines up to date as per DAIT guidance for patients in interventional transplant trials of investigational immunosuppression. Exclusion Criteria: * Inability or unwillingness of a participant to give documented informed consent or comply with the study protocol. * History of retransplantation or multi-organ transplantation. * Split liver transplantation, except when involving a right tri-segment. * Liver transplantation indication of autoimmune disease. * Use of mTOR inhibitor during the prior 3 months. * Any post-transplant diagnosis of malignancy (except basal cell carcinoma of skin) or recurrent hepatocellular carcinoma. * Active, uncontrolled systemic infection at enrollment. * Known history of infection with human immunodeficiency virus (HIV). * Pregnancy, breastfeeding, or plans to become pregnant during the study period. * History of mental illness or substance abuse that could impact study compliance, as judged by the investigator. * Any past or current medical history, physical examination findings, or laboratory test results not specified above, which, in the opinion of the investigator, may present additional risks, hinder compliance, or affect data quality or interpretation for this study.